Eurofins Scientific SE · EURONEXT:ERF
Eurofins Scientific — Investor Presentation (September 2020)
117 slides from Eurofins Scientific's investor presentation, September 2020
Slide 1: Eurofins Corporate Presentation September 2020
Eurofins The global leader in bioanalytical testing in the food, environment, pharmaceutical, agrosciences, cosmetics products testing and clinical sectors Consistently delivering strong, sustainable, profitable growth Doubled revenues more than 3 times (every 4 years on average) between 2005 and 20
Slide 2: Disclaimer
Disclaimer The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain
Slide 3: Contents
Contents ▪ Executive Summary ▪ Market & Strategic Positioning ▪ Financial review ▪ ESG ▪ Outlook ▪ Summarised Financial Statements ▪ Appendix 3
Slide 4: H1 2020 Financial Highlights
H1 2020 Financial Highlights Revenues €2,323m +7.2% yoy +5.1% organic growth Adjusted EBITDA €493m +18.9% yoy 21.2% of revenues, +210 bps yoy Reported EBITDA €459m +23.6% yoy 19.7% of revenues, +260 bps yoy Free Cash Flow to the Firm €315m +184.5% yoy Adjusted EPS €10.30 +16.6% yoy Reported EPS €5.2
Slide 5: H1 2020 Business Highlights
H1 2020 Business Highlights • Eurofins end-markets, which are part of essential supply chains, proved to be more resilient than many other segments • Our teams were able to develop in record time a unique and comprehensive suite of testing services and scientific solutions to support the efforts of
Slide 6: Eurofins' Mission is to contribute to global Health, Safety & Environment
Eurofins’ Mission is to contribute to global Health, Safety & Environment with the best in bioanalysis ▪ Founded in 1987 Eurofins provides testing ▪ IPO in 1997 in Paris at €1.83 per share (vs. €558.60 at 30 June 2020) services in four main areas ▪ Over 48,000 employees across network of over 900 in
Slide 7: Drivers for high long-term above GDP market growth
Drivers for high long-term above GDP market growth Secular Underlying Fundamentals General Market Drivers Laboratory Market Drivers Demand for safe Consumer Increasing wealth pharmaceuticals, quality food expectations for and clean environment and quality of Life protection Consolidation of the frag
Slide 8: Innovations: TruGraf and Other Specialised Transplant Tests
Some of Eurofins’ Innovations: TruGraf and Other Specialised Transplant Tests ➢ Background ➢ Eurofins acquired US-based Transplant Genomics Inc. (“TGI“) as a pre-revenue company in May 2019 ➢ TGI had developed a test, called “TruGraf®“ to rule out subacute / silent kidney rejection in transplant pat
Slide 9: Innovations: Leader in Non-Invasive Prenatal Testing
Some of Eurofins’ Innovations: Becoming Leader in Non- Invasive Prenatal Testing (NIPT) in Europe thanks to our R&D ➢ Eurofins is the No 1 player in the fast growing European NIPT market with ca. 150,000 non-invasive prenatal tests performed in 2019 vs. ca. 100,000 tests in 2018 ➢ Eurofins offer a v
Slide 10: Innovations: Non-Invasive Prenatal Testing (NIPT) in Europe
Some of Eurofins’ Innovations: Becoming Leader in Non- Invasive Prenatal Testing (NIPT) in Europe thanks to our R&D Eurofins LifeCodexx: ➢ In December 2016, Eurofins LifeCodexx launched the worldwide first non-invasive prenatal test (NIPT) assay based on a quantitative real-time PCR for prenatal tes
Slide 11: Innovations: Onconext Next Generation Oncology Diagnostics
Some of Eurofins’ Innovations: Onconext - Next Generation Oncology Diagnostics ➢ Onconext from Eurofins Genoma is an advanced molecular diagnostics solution for personalised cancer care that uses state of the art technology ➢ The team comprises multidisciplinary professionals specialized in molecula
Slide 12: Innovations: Onconext Next Generation Oncology Diagnostics
Some of Eurofins’ Innovations: Onconext - Next Generation Oncology Diagnostics 12
Slide 13: Eurofins in high growth Life Sciences markets critical for COVID-19
Eurofins is also present in several high growth Life Sciences markets which are critical for battling the COVID-19 pandemic Oligonucleotides Production and In Vitro Diagnostic (IVD) products Next Generation Sequencing (NGS) #3(1) worldwide Eurofins’ Start-up #1(1) in Europe position Start 2016 Start
Slide 14: Life Sciences and IVD products to fight COVID-19
Life Sciences and In Vitro Diagnostic (IVD) products to fight the COVID-19 pandemic Eurofins Technologies • GeneScan VIRSeek RT-PCR - testing kits and reagents for detection of SARS- CoV-2 in swabs of environmental surfaces SARS-CoV-2 may remain viable on ✓ Helps employers evaluate the effectiveness
Slide 15: ELISA high-throughput automation platforms
ELISA high-throughput automation platforms Gold Standard Diagnostics (GSD) offers industry-leading ELISA analysers ✓ Low total cost of ownership for instrumentation, consumables, customer support ✓ Innovative, industry-leading open platform instruments: ThunderBolt® and the Bolt The ThunderBolt® The
Slide 16: Focus on Scientific Innovation: 2019 examples
Focus on Scientific Innovation: 2019 examples ➢ Example 1: Detecting Microplastic in Food ➢ Growing issue of microplastic affecting the food and environment ➢ Microplastic potentially harms nature, animals and human health ➢ A Eurofins laboratory in Australia is the first laboratory offering commerc
Slide 17: Strong Organic Growth in H1 2020 despite COVID-19 disruptions
Strong Organic Growth in H1 2020 despite COVID-19 disruptions • 5.1% organic growth in H1 2020* • 6.1% organic growth in Q2 2020* • Strong organic growth compared to peers & three large in vitro diagnostic device (IVD) suppliers Peers H1 2020 Organic Growth*** Prominent IVD actors H1 2020 Organic Gr
Slide 18: Attractive and resilient organic growth characteristics
Building leadership positions in an industry with attractive and resilient organic growth characteristics ➢ Market Structural growth: est. ~1.5-2x Gross Domestic Product (GDP) growth, globalisation, urbanisation, increasing need and demand for a healthier life and safer environment. Testing is the m
Slide 19: Strengthened Group Leadership in the Last 3 Years
Eurofins has Significantly Strengthened its Group Leadership in the Last 3 Years ➢ Eurofins has enhanced its leadership by adding six new members to its Group Operating Council (GOC) over the last three years Yvoine McCort Mark Thys Senior Vice President Environment Testing Europe Chief Transformati
Slide 20: 2020 growth plan update: hub and spoke laboratories platform
2020 growth plan update: building a one of a kind hub and spoke laboratories infrastructure platform for global leadership in our markets – Large hub laboratories capture scale advantage ➢ Building large high throughput laboratory campuses (hubs of the hub and spoke structure) Added or brought to mo
Slide 21: Start-ups an increasingly attractive investment
Start-ups an increasingly attractive investment as we leverage our scale and experience 160 laboratories start-ups between 2000 and 2019 Substantial acceleration offers tremendous growth potential 1) Acceleration in laboratories start-up programmes ➢ 25 start-ups 2000-2009 (Programme 1) ➢ 18 start-u
Slide 22: TestAmerica Acquisition, Cost Base & Cost Management
TestAmerica Acquisition Cost Base & Cost Management 22
Slide 23: Experienced in integrating acquisitions
Eurofins is experienced in successfully integrating acquisitions and is returning to its historic M&A run rate ➢ M&A has always been an integral part of Eurofins long-term strategy to build a unique bioanalytical testing platform for global leadership in its attractive high growth and very scalable
Slide 24: Margin Development – Mature Scope of Business
Margin Development – Mature Scope of Business In €m 2017 2018 2019 Mature scope revenues 2,714 3,505 4,315¹ Mature scope as % of total revenues 91% 93% 93%¹ 20.5% 20.5%¹ Adjusted EBITDA margin of mature scope 20.5% Stable Stable Adjusted EBITDA margin of mature scope created or 21.2% 21.6%¹ 20.7% ac
Slide 25: Objectives: €5bn revenues in 2020 and €5.45bn in 2021
Objectives are to achieve €5bn revenues in 2020 (vs. €4bn originally planned in 2015 for 2020) and €5.45bn revenues in 2021 Illustration of Eurofins’ 2020-2021 growth objectives assuming constant/linear acquisition volume and growth rate each year Eurofins’ objective updated on 04 March 2020 is to a
Slide 26: Resilient end-markets & portfolio of solutions to fight COVID-19
Resilient end-markets & unique portfolio of solutions to help fight COVID-19 • Our end-markets have proven very resilient once again as during the 2008- 2009 great recession, across most geographies • Few companies have so many scientific and technological possibilities to develop new solutions and
Slide 27: Main initiatives to help fight the COVID-19 pandemic
Highlight of main initiatives to date to help fight the COVID-19 pandemic Aside from PCR and serologic antibodies testing activities: Eurofins is very active in the areas of Genomics and Biopharmaceutical testing services to support accelerated COVID-19 drug and vaccines development, full-length Gen
Slide 28: Eurofins SAFER@WORK programme
Eurofins SAFER@WORKTM programme • Eurofins SAFER@WORKTM programme is a suite of integrated risk-based solutions for businesses to keep staff and customers safer during the COVID-19 pandemic • SAFER@WORK brings together expertise from several Eurofins’ business lines: • Clinical Diagnostics – PCR and
Slide 29: Eurofins Sentinel early detection of COVID-19 spreaders
Eurofins SentinelTM a cost-effective method for early detection of asymptomatic COVID-19 spreaders that doesn’t require human PCR clinical testing • Eurofins COVID-19 SentinelTM portfolio of tests: • Allows for early detection of virus presence at a given site, before the virus spreads too broadly,
Slide 30: Contents
Contents ▪ Executive Summary ▪ Market & Strategic Positioning: Overview of Markets Served & Structure ▪ Financial review ▪ ESG ▪ Outlook ▪ Summarised Financial Statements ▪ Appendix 30
Slide 31: Leading market positions in high-growth markets (1/2)
Leading global and local market positions in attractive high-growth markets* (1/2)… Testing for Food & Feed Environment Clinical Pharma/Biotech/Agrosciences Testing Testing Diagnostics N°1 to N°3* N°1* N°1* Start-Up Eurofins position worldwide worldwide worldwide Start 2014 Start 2000-2005 Start 198
Slide 32: Leading market positions in high-growth markets (2/2)
Leading global and local market positions in attractive high-growth markets* (2/2) Testing for Food & Feed Environment Clinical Pharma/Biotech/Agrosciences Testing Testing Diagnostics N°1 to N°3* N°1* N°1* Start-Up Eurofins position worldwide worldwide worldwide Start 2014 Start 2000-2005 Start 1987
Slide 33: Eurofins Pharma Services in more detail
Eurofins Pharma Services in more detail Spanning the entire drug development cycle Genomics Discovery Pre-clinical/ Clinical Development BioPharma Pharmacology Early (Central & Products Development Laboratory/ Manufacturing Testing Bioanalytical) (CDMO) Sequencing High-throughput- Pharmacology Bioma
Slide 34: Leadership positions with network effects and competitive advantage
Building leadership positions in an industry with significant network effects and competitive advantage for the market leader High level of investment and innovation required to build and efficiently run a network of modern laboratories (buildings, equipment, IT High barriers infrastructure and solu
Slide 35: Unique platform for global leadership with network effects
Building a unique platform for global leadership in our attractive high growth markets with large network effects High barriers to entry exist in Eurofins’ markets. Significant investments are required to build and efficiently run modern laboratories. Clients seldom change laboratory supplier. ➢ Con
Slide 36: Hub and spoke laboratory platform in U.S. Food testing
Since 2015, Eurofins has built a one of a kind hub and spoke laboratories infrastructure platform in the U.S. Food testing market – Hub and spoke model allows for cost-effective and timely delivery of high quality testing results ➢ Eurofins is structuring its unique network of laboratories using the
Slide 37: Building the Platform – Eurofins 2012 - Eurofins 2020
Building the Platform – Eurofins 2012 - Eurofins 2020 Progress to Date 2012-2019 ∆ 2012 2015 2019 +7 years Revenues (€ m) 1,044 1,950 4,563 23% CAGR Employees 10,890 18,382 43,320 22% CAGR (average FTE) Number of laboratories 170 225 >800 Over 4x (year-end) Number of countries 34 39 >50 >16 7 Food a
Slide 38: Leader in most of its markets and building global leadership
Eurofins is the leader in most of its markets and continues to build global & local leadership positions* in markets where scale matters New Markets 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Denmark: Food and Environment Testing Sweden, Norway: Fo
Slide 39: Revenues from markets with global leadership positions
Overall, a large majority of Eurofins’ revenues come from markets where the Group has established global leadership positions Business Line Global leadership position Food & Feed testing ✓ Environment testing ✓ Clinical Diagnostics BioPharma Product Testing (BPT) ✓ Consumer Product Testing Early Dev
Slide 40: Present in countries generating over 86% of world GDP
Eurofins is already present in countries generating over 86% of the world’s GDP… but still has lots of room to grow International Monetary Fund Eurofins market presence (Estimates as of October 2019) (To the best of Eurofins’ knowledge, based on data available to the Group) Environment Country GDP (
Slide 41: 1987 – 2019: Building a unique global network
1987 – 2019: In only 32 years we built a unique global network 1987 From 1 laboratory in Nantes (France) in 1987… 2019 4 … to more than 800 laboratories around the world in 2019! over 48,000 employees employees … now operating in over 50 countries! Eurofins’ site map as of January 2020 41
Slide 42: Global trends in regulation support the business
Global trends in regulation support the business ▪ Strongly regulated markets (EU, U.S.) are still amending and adding regulations ▪ Eastern European countries catching up with EU regulations ▪ Fast development of regulation in Asia ▪ Regulation used for support of trading blocks (e.g. EU, NAFTA, AS
Slide 43: Outsourcing adds to market growth
Outsourcing adds to market growth Examples of laboratories outsourced to Eurofins Company Outsourced Activity Country Axéréal & Terrena Galys agricultural laboratories France Signify Materials Analysis and Reliability The Netherlands Astellas Astellas Analytical Science Labs Japan Danish Hydrology I
Slide 44: Meaningful industry consolidation is underway
Meaningful industry consolidation is underway Selection of recent significant transactions in the testing industry Date Company Acquirer Geography Sales (€m) EV (€m) EV/Sales (x) EV/EBITDA (x) 2019 November LGC Cinven and Astorg UK 525 3,519 6.7x 17.1x July Genomic Health Exact Sciences US 507 2,816
Slide 45: Strategy building long lasting competitive advantage
Eurofins’ strategy aims at building long lasting competitive advantage in very attractive markets Leading technology Quality of customer service ▪ Competence Centres & R&D activities ▪ Extensive expertise in local regulations for all major markets, and one-stop contact for ▪ Proprietary technologies
Slide 46: Family-owned businesses outperform their peers
Credit Suisse report shows that family-owned businesses outperform their peers* …supported by superior growth and Profitability Revenue and EBITDA growth is stronger, EBITDA margins are higher and cash flow returns are better. Family-owned companies also appear to have a greater focus on innovation
Slide 47: Contents
Contents ▪ Executive Summary ▪ Market & Strategic Positioning ▪ Biopharma Testing Services ▪ Food Testing ▪ Environment Testing ▪ Clinical Diagnostics ▪ Other ▪ Financial review ▪ ESG ▪ Outlook ▪ Summarised Financial Statements ▪ Appendix 47
Slide 48: The Pharma testing market is healthy and full of potential
The Pharma testing market is both healthy and full of potential Need for big pharma Rapid technological change & companies to expand increasing complexity in testing new drugs pipelines require ongoing investment in technology & expertise ▪ The increasing complexity of clinical trials leads to incre
Slide 49: Underlying trends intact for continued growth
Underlying trends are intact for continued growth Worldwide Drug R&D Spending ($ bn) ▪ Pharmaceutical and biotechnology R&D spending is expected to rise to $182bn in 2019 ▪ In 2019 the FDA approved 48 novel drugs* ▪ In 2019 the FDA approved 10 new biosimilars* ▪ As patents for biologics expire in th
Slide 50: More than 90% of top 20 biopharma companies are clients
More than 90% of the top 20 largest global biopharma companies are clients of Eurofins Eurofins biopharma locations Global CRO Market Outlook Top 10 global biopharma companies Pfizer (US) Roche (CH) Novartis (CH) Johnson & Johnson (US) Merck & Co (US) Sanofi (FR) AbbVie (US) GlaxoSmithKline (UK) Amg
Slide 51: Contents
Contents ▪ Executive Summary ▪ Market & Strategic Positioning ▪ Biopharma Testing Services ▪ Food Testing ▪ Environment Testing ▪ Clinical Diagnostics ▪ Other ▪ Financial review ▪ ESG ▪ Outlook ▪ Summarised Financial Statements ▪ Appendix 51
Slide 52: The Food testing market enjoys robust growth drivers
The Food testing market enjoys robust growth drivers Food scares and Globalisation: Raw Consumers’ Outsourcing of crises, widely materials sourced increasing awareness industry’s covered in the from countries and demand for safe internal or state- media with different QC and high quality food owned
Slide 53: Most comprehensive Food & Feed testing offering
Eurofins’ Food & Feed testing offering is the most comprehensive in the market Agricultural production, product Production Retail & Distribution development Microbiology Sensorial Dioxins Veterinary drug Vitamins Quality Control residues Authenticity Pesticides Organic residues POPs Labelling GMO My
Slide 54: High profile food scares have expensive consequences
High profile food scares have expensive consequences for producers… Brand / Year Contamination Impact Cost Source Country 2019 Wilke Listeria outbreak Over 1,000 items recalled across European retailers/supermarkets Unquantified Food Safety Waldecker contaminating meat News / The Fleisch- und produc
Slide 55: Meeting the demands of global players
Eurofins is meeting the demands of global players for high quality testing ▪ The largest global food & beverage producers and retailers are clients of Eurofins Food and Beverage Retailers Nestlé Switzerland Wal-Mart Stores USA PepsiCo USA CostCo USA Unilever UK /Netherlands Kroger USA Mars USA Lidl
Slide 56: Contents
Contents ▪ Executive Summary ▪ Market & Strategic Positioning ▪ Biopharma Testing Services ▪ Food Testing ▪ Environment Testing ▪ Clinical Diagnostics ▪ Other ▪ Financial review ▪ ESG ▪ Outlook ▪ Summarised Financial Statements ▪ Appendix 56
Slide 57: The Environmental testing market continues to grow
The Environmental testing market continues to grow Rise in Progress in epidemiology contamination & & medicine has identified pollution issues more compounds as toxic ▪ Increasing demand by citizens for a clean environment ▪ EU expanding regulation (e.g. REACH) ▪ Increasingly long list of products i
Slide 58: Eurofins serves all the main environmental testing markets
Eurofins serves all the main environmental testing markets Eurofins is the No.1 environmental testing service provider in the world* Consulting and sampling companies are natural partners Lancaster Environmental Testing is the laboratory of choice for Fortune 500 companies in the USA WATER AIR SOIL
Slide 59: Contents
Contents ▪ Executive Summary ▪ Market & Strategic Positioning ▪ Biopharma Testing Services ▪ Food Testing ▪ Environment Testing ▪ Clinical Diagnostics ▪ Other ▪ Financial review ▪ ESG ▪ Outlook ▪ Summarised Financial Statements ▪ Appendix 59
Slide 60: Global network of clinical genetics laboratories
Eurofins is setting up a global network of clinical genetics laboratories ▪ Nowadays, Clinical Genetics is a central element in healthcare and Clinical Diagnostics, contributing to every stage of patient care ▪ Throughout all three of Eurofins’ start-up programs, several large investments in global
Slide 61: Expanding global offering in non-invasive prenatal testing
Eurofins is expanding its global offering in non-invasive prenatal testing (NIPT) In September 2017, Eurofins’ Genoma introduced GeneSafeTM, the first non-invasive prenatal test that screens for both de novo (non-inherited gene mutations) and inherited single-gene disorders. ➢ GeneSafeTM detects ove
Slide 62: Specialized Clinical Diagnostic Network Evolution
Eurofins Specialized Clinical Diagnostic Network Evolution “Genomics is one of the key technologies enabling personalized medicine…” Establishing platform to deploy genomics expertise for development of innovative clinical diagnostic tests to serve global healthcare community One of the world’s lead
Slide 63: Specialised Clinical Diagnostic Footprint
Eurofins Specialised Clinical Diagnostic Footprint Establishing leadership in targeted higher-growth niche areas of the clinical testing market Humangenetik Dr. Finckh Dortmund Clinical Genetics Japan 63
Slide 64: Routine and Specialized Clinical Diagnostics Laboratories in France
Eurofins has built a valuable portfolio of Routine and Specialized Clinical Diagnostics Laboratories in France ➢ Eurofins Clinical Diagnostics operations in France amount to ca. €400m of revenues. ➢ These €400m revenues were acquired over the last 4 years for ca. €600-700m, representing an average E
Slide 65: Growth of U.S. listed Specialized Clinical Diagnostics companies
Half-year 2019 Growth of U.S. listed Specialized Clinical Diagnostics companies (Figures in $ m) YTD share Enterprise EV / H1 2019 H1 2018 Total Organic EV / Company price Value FY18 Revenues Revenues Growth growth* FY18 Sales growth** (EV)** EBITDA Myriad Genetics 432.0 377.0 14.6% 0.7% -1% 2,185 2
Slide 66: Contents
Contents ▪ Executive Summary ▪ Market & Strategic Positioning ▪ Biopharma Testing Services ▪ Food Testing ▪ Environment Testing ▪ Clinical Diagnostics ▪ Other ▪ Financial review ▪ ESG ▪ Outlook ▪ Summarised Financial Statements ▪ Appendix 66
Slide 67: Global leadership in 5 high potential niche markets
Eurofins has also established global leadership positions in 5 high potential niche markets Agroscience CRO** Cosmetics Advanced Materials Genomic Services Discovery Pharmacology Services Testing Sciences N°2* Worldwide N°1* N°1* N°1* N°1* Eurofins N°1* worldwide worldwide worldwide worldwide positi
Slide 68: High Barriers to Entry around its businesses
Eurofins is developing high Barriers to Entry around its businesses Offering a premium quality service … ... and leveraging internal efficiencies ▪ Portfolio: over 200,000 analytical ▪ Industrialising the laboratory process: methods – unique in the world and ahead rationalisation of sites and person
Slide 69: Contents
Contents ▪ Executive Summary ▪ Market & Strategic Positioning ▪ Financial review ▪ ESG ▪ Outlook ▪ Summarised Financial Statements ▪ Appendix 69
Slide 70: Positive trends drive solid operating results
Positive trends drive solid operating results FY 2019 (including IFRS 16) FY 2018 +/- % +/- % In €m except otherwise stated Adjusted1 Separately Reported Adjusted Separately Reported Adjusted Reported Results* disclosed Results Results disclosed Results Results Results items2 items Revenues 4,562.8
Slide 71: FY 2019 comparable adjusted results excluding IFRS 16 and cyber-attack
FY 2019 comparable adjusted results excluding IFRS 16 and cyber-attack impacts ➢ 2019 reported results are not easily comparable as a result of the major impact of the 02 June 2019 cyber-attack on Eurofins’ operations and of the implementation of IFRS 16 on Eurofins’ accounts. The table below attemp
Slide 72: Investments linked to 2016-2020 investment plan
Investments linked to Eurofins’ 2016-2020 investment plan should provide long-term returns once the Group has reached the optimal footprint in its markets and geographies In 2019 Eurofins continued to deploy capital to become the leading and most competitive player in its markets: ➢ €171m in selecti
Slide 73: Separately disclosed items should continue to decrease
Eurofins separately disclosed items (SDIs) should continue to decrease gradually • H1 2020 SDIs as a percentage of adj. EBITDA have decreased significantly year-on-year as Eurofins is close to finalising its 2015-2020 programme to build the laboratory infrastructure network of a global leader in Tes
Slide 74: Free cash flow allocated to building global platform
Eurofins has been allocating a significant part of its free cash flow to equity towards building its leading global platform Cashflow expansion levers: cash investments impacting cashflows +€121m (€92m estimated cyber- 500 attack cost & cash flow impact, €29m for purchase of 2 buildings at year- end
Slide 75: Investments to build optimal global laboratory footprint
Investments to build optimal global laboratory footprint Capex remains driven by network expansion investments Continuous investments in state-of-the-art IT solutions 400 12.0% 40 350 -18% 35 10.0% 30 300 +42% 8.0% 25 IT Capital Expenditures (€m) Net Capital Expenditures (€m) 250 +34% 20 Net Capex/S
Slide 76: Net Working Capital as % of sales
Net Working Capital as % of sales ➢ 4.5% net working capital (NWC) to sales objective in line with past performance ➢ 2017 and especially 2018 negatively impacted by large acquisitions with longer collection times ➢ 2019 negatively impacted by the cyber-attack (on billing and dunning systems and cli
Slide 77: Objectives for adjusted EBITDA and free cash flow 2020-2021
Objectives to reach €1.1bn and €1.25bn adjusted EBITDA and €500m and €600m Free Cash Flow to the Firm** in 2020 and 2021 respectively, and to bring leverage back to ca. 2.5x by end of 2020 Eurofins Cashflow Expansion Levers In spite of 20 start-ups per year (average past 5 Objectives*: years) Separa
Slide 78: Free Cash Flow to the Firm objectives 2020-2021
Free Cash Flow to the Firm* (FCFF): objectives 2020 - 2021 (€m) 700 € 600m** 600 € 500m** 500 € 379m 400 € 29m € 37m € 55m 300 € 258m 200 100 0 FCFF FY lost operating NWC drag Buildings FCFF FY Capex spend NWC Cyber Operating FCFF FY Capex spend NWC Cyber Operating FCFF FY 2019 incl. profit (net of
Slide 79: Return on Capital Employed
Return on Capital Employed (EURm) 2016 2017 2018 2019 Average capital employed at the end of each quarter 2,399 2,803 4,521 5,851³ Average capital employed excluding Goodwill at the end of each quarter 657 785 1,080 1,472 Adjusted EBITAS² 358 400 521 626 ROCE¹ (return on capital employed) 14.9% 14.3
Slide 80: Well financed for the mid-term with strong liquidity
Eurofins is well financed for the mid-term and has strong liquidity The majority of Eurofins’ debt instruments bear low fixed interest rates for long maturities Bond, Schuldschein & Hybrid Capital Maturity Profile Over the years, strict financial discipline has allowed Eurofins to significantly redu
Slide 81: Solid Balance Sheet
Solid Balance Sheet Equity Dec 2019 H1 2020 (in €m) incl. IFRS 16* ▪ Equity issuance of €535m on 18 May 2020 Hybrid – Ba2 rated ▪ Net Debt/ Comparable1 2.53x 3.24x Adjusted EBITDA ▪ €300m hybrid issued in September 2019, callable at par by Eurofins in August/September 2022. Bears a fixed coupon of ▪
Slide 82: High Degree of Financial Flexibility
High Degree of Financial Flexibility Strong Balance Sheet as of 30 June 2020 Leverage* ratio pre IFRS 16 4.00 x 3.68 x ▪ Leverage* ratio back below historical self-imposed limit of 3.5x 3.50 x 3.24 x ▪ Large financial flexibility with fairly long financing 3.08 x maturity 3.00 x • Hybrid capital of
Slide 83: Strong financial discipline at all times
Strong financial discipline at all times Leverage* 4.00 x About 60 acquisitions with total annualized About 50 acquisitions with total annualized revenue revenue contribution of ca. €700m. contribution of ca. €720m. Entry into 5 new countries Entry into 3 new countries 30 start-ups 15 start-ups Over
Slide 84: Audit Coverage Continued Expansion
Audit Coverage Continued Expansion ➢ In 2019, the AGM appointed Deloitte Audit as new auditor resulting in improved audit coverage by Tier 1 and Tier 2 auditors FY 2019 accounts FY 2018 accounts Deloitte Audit Tier 1 & Tier PwC Tier 1 & Tier coverage for 2 auditors coverage for 2 auditors Consolidat
Slide 85: Contents
Contents ▪ Executive Summary ▪ Market & Strategic Positioning ▪ Financial review ▪ ESG ▪ Outlook ▪ Summarised Financial Statements ▪ Appendix 85
Slide 86: Business aligned with 15 of 17 UN Sustainable Development Goals
Eurofins’ business is aligned with 15 of the 17 United Nations Sustainable Development Goals Eurofins’ Mission: To contribute to a safer and healthier world by providing its customers with innovative and high quality laboratory, research and advisory services whilst creating opportunities for its em
Slide 87: 2019 Corporate Governance Improvements
Some of 2019 Corporate Governance Improvements ➢ Key Governance document additions including: ➢ Anti-Bribery Policy, Fair Competition Policy, Modern Slavery Statement, Equal Opportunities and Fair Employment Policy, Health and Safety Policy, Whistleblowing Policy, Supplier Code of Ethics, Privacy Po
Slide 88: Related Party Transactions: Robust Audited Process
Related Party Transactions: Robust Audited Process to ensure Arms’ Length Terms ➢ Corporate Governance (CG) Committee ensures that rentals with related parties are complying with best governance practice, especially with regards to: ▪ Non-implication from related parties in the internal decision mak
Slide 89: Environmental Matters Improvements 2019
Environmental Matters Improvements 2019 ➢ Carbon emissions for Eurofins Group estimated for the first time (disclosure on methodology and outcome on next slide) ➢ Carbon footprint reduction measures ➢ A number of programmes running across the Group ➢ Carbon Compensation Programme 2019 ➢ Offset of 53
Slide 90: Carbon emissions calculation
Carbon emissions calculation ➢ CO2 emissions calculation ➢ Calculation of Eurofins‘ carbon footprint ➢ Performed by specialised external advisor, CO2logic¹ conforming with ISO 14064 and European Emissions Trading Scheme ➢ Based on 8 Eurofins laboratories in North America and Europe covering 4,799 FT
Slide 91: Livelihoods Funds Investment
Livelihoods Funds Investment ➢ Investment ➢ Livelihoods Carbon Fund (LCF), an impact investment fund supporting the restoration and conservation of natural ecosystems in developing countries while improving the lives of the local communities ➢ 12 million tons of CO2 to be sequestered over 20 years ➢
Slide 92: Social Matters Improvements 2019
Social Matters Improvements 2019 ➢ Social Highlights ➢ Over 20 laboratories with more than 1,000 FTE workforce are voluntarily accredited by ISO 45001 / OHSAS 18001 (occupational health and safety) ➢ Eurofins tracks TRIR¹ for more than 10,000 employees in the USA. TRIR in 2019 stood at 1.5 (unchange
Slide 93: Contents
Contents ▪ Executive Summary ▪ Market & Strategic Positioning ▪ Financial review ▪ ESG ▪ Outlook ▪ Summarised Financial Statements ▪ Appendix 93
Slide 94: Outlook: becoming the world leader in bioanalytical testing
Outlook: becoming the world leader in the bioanalytical testing market Sustainable Market Growth Drivers + Key Success Factors = Solid Outlook* ▪ Food safety & contamination ▪ Unique technological portfolio of 2020 Objectives issues over 200,000 methods ➢ €5.0bn Revenues ➢ €1.1bn Adjusted EBITDA ▪ N
Slide 95: Conclusion: our sustainable competitive advantage
Conclusion: our sustainable competitive advantage Best in class technology and quality give best brand High-growth, non-cyclical markets driven by secular protection mega-trends N° 1 or 2 worldwide in most business lines Advancing globalisation but with very few global Operating in more than 50 coun
Slide 96: Contents
Contents ▪ Executive Summary ▪ Market & Strategic Positioning ▪ Financial review ▪ ESG ▪ Outlook ▪ Summarised Financial Statements ▪ Appendix 96
Slide 97: Consolidated Income Statement
Consolidated Income Statement Consolidated Income Statement (2019 figures include IFRS 16 impact) For the year ended 31 December 2019 2019 2018 Separately Separately EUR Millions Adjusted results Reported results Adjusted results Reported results disclosed items disclosed items Revenues 4,562.8 4,56
Slide 98: Consolidated Balance Sheet
Consolidated Balance Sheet Consolidated Balance Sheet (2019 figures include IFRS 16 impact) EUR Millions 31 December 2019 31 December 2018 Property, plant and equipment 1,593.5 1,018.0 Goodwill 3,608.8 3,418.3 Other intangible assets 918.2 946.9 Investments in associates 5.3 5.1 Financial assets and
Slide 99: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Consolidated Cash Flow Statement (2019 figures include IFRS 16 impact) For the year ended 31 December 2019 EUR Millions 2019 2018 Restated* Cash flows from operating activities Profit before income taxes 271.5 289.8 Adjustments for: Depreciation and amortisation 395.
Slide 100: IFRS 16 impact on Income Statement
IFRS 16 impact on Income Statement FY 2019 FY 2019 FY 2018 IFRS 16 excluding Reported Reported impact IFRS 16 Results Results In EUR m Revenues 4,562.8 - 4,562.8 3,781.1 Operating costs, net -3,860.6 130.8 -3,729.8 -3,129.7 EBITDA 702.2 130.8 833.0 651.4 Depreciation and amortisation -285.1 -110.8 -
Slide 101: IFRS 16 impact on Balance Sheet
IFRS 16 impact on Balance Sheet FY 2019 FY 2019 FY 2018 In EUR m excluding IFRS 16 impact Reported Reported IFRS 16 Results Results Property, plant and equipment 1,106.2 487.3 1,593.5 1,018.0 Goodwill 3,608.8 3,608.8 3,418.3 Other intangible assets 918.2 918.2 946.9 Investments in associates 5.3 5.3
Slide 102: IFRS 16 impact on Cash Flow Statement
IFRS 16 impact on Cash Flow Statement FY 2019 IFRS 16 FY 2019 FY 2018 In EUR m excluding Impact Reported Reported IFRS 16 Cash flows from operating activities Restated* Profit before income taxes 278.7 -7.2 271.5 289.8 Adjustments for: Depreciation and amortisation 285.1 110.8 395.9 223.7 Share-base
Slide 103: Contents
Contents ▪ Executive Summary ▪ Market & Strategic Positioning ▪ Financial review ▪ ESG ▪ Outlook ▪ Summarised Financial Statements ▪ Appendix 103
Slide 104: Legal structure aligned with leadership structure
Eurofins legal structure is very straightforward, aligned with its leadership structure by country and area of activity and set up to foster entrepreneurship • Eurofins’ structure fosters entrepreneurship: • Small, agile legal entities → 1 managing director / president in charge of each entity with
Slide 105: Post-acquisition transfer of activities: Exova example
Companies acquired are usually too diversified and their activities need to be transferred to the respective legal entities post-acquisition Example: Eurofins acquisition of Exova in 2016 ▪ Exova 2016 Limited was acquired by Eurofins Food Testing LUX Holding in 2016 ▪ Exova 2016 Limited was servicin
Slide 106: Site Footprint Evolution 2016 to 2019 – Food and Water Testing UK
Site Footprint Evolution from 2016 to 2019 – Food and Water Testing UK including Exova Illustrative example Before reorganisation After reorganisation to optimise footprint 2016 2019 Hillington Livingston Ashwood (2017 acquisition) Newtec Harrogate (2018 acquisition Covance) Hull Hull Grimsby Grimsb
Slide 107: Eurofins legal structure in the U.K.
Eurofins legal structure in the U.K. Food and BioPharma Product Testing example Food Testing BioPharma Product Testing Real Estate Entities Administration Entities Eurofins Food Eurofins Eurofins Wolverhampton Livingston Southern Eurofins Integrity Testing Eurofins Food BioPharma Professional i54 Re
Slide 108: Local vs. Group Impairments
Local vs. Group Impairments ➢ Impairments at the local level are not automatically reflected in the Group’s consolidated accounts for the following main reasons: Local Statutory Accounts Consolidated Accounts Local GAAP IFRS standards Accounting These may differ (applicable legislation for preparing
Slide 109: Vastly outperformed the market since its IPO
Eurofins has vastly outperformed the market since its IPO (based on share price of €558.60 as of 30 June 2020) Eurofins: +30,435% (29% 22-year CAGR) 34000% CAC 40: +78% (3% 22-year CAGR) 33000% SBF 120: +106% (3% 22-year CAGR) 32000% S&P 500: +254% (6% 22-year CAGR) Oct 2017 May 2020 31000% ABB** AB
Slide 110: Shareholder Returns: TICS & Clinical Diagnostics Companies
Shareholder Returns: TICS & Clinical Diagnostics Companies Shareholder Returns (based on share prices as of close 31.12.2019) Based on share prices Total Shareholder Returns (Assumes all dividends re-invested) Dec-11 Dec-12 Dec-13 Dec-14 Dec-15 Dec-16 Dec-17 Dec-18 Dec-19 Dec-11 Dec-12 Dec-13 Dec-14
Slide 111: Shareholder Returns: TICS & Clinical Diagnostics Companies
Shareholder Returns: TICS & Clinical Diagnostics Companies Historical Share Price Development (Y vs Y-1) Compounded Growth 2Y 3Y 4Y 5Y 5Y 2018- 2017- 2016- 2015- Dec-13 Dec-14 Dec-15 Dec-16 Dec-17 Dec-18 Dec-19 Growth 2019 2019 2019 2019 Eurofins 60.4% 7.9% 51.8% 25.8% 25.3% -35.8% 51.6% 133.1% -1%
Slide 112: New warrants program for key leaders
New warrants program highlights the long-term commitment of Eurofins’ key leaders and their trust in the growth potential of the Group Upside/Downside for warrant holders ➢ In June 2018, Eurofins issued 124,460 warrants exclusively to the Group’s top leaders ➢ Exercise Price €529.65 ➢ Purchase Price
Slide 113: Heavy investment in high-growth markets and resources
Heavy investment in high-growth markets and resources for future profits Bringing recently acquired Building corporate resource laboratories to group Network Investments for future size and growth standards ▪ €1.78 bn total investments in ▪ Recruitment of top ▪ Deploy proprietary IT laboratory netwo
Slide 114: Net Capex to Sales
We have built a hard-to-replicate world-class infrastructure Eurofins has been consistently investing more than its peers (average if more than 1 year) 12% 180% 160% 10% 140% 8% 120% Net Capex to Sales 100% 6% 80% 4% 60% 40% 2% 20% 0% 0% 00-'04 05-'09 2010 2011 2012 2013 2014 2015 2016 2017 2018 201
Slide 115: M&A in attractive niche markets
M&A in attractive niche markets ➢ 26 bolt-on acquisitions in FY 2019, with total spend of EUR 171m, well below the Group’s annual objective to spend up to EUR 300m on M&A ➢ In 2019, these 26 companies generated revenues in excess of EUR 130m ➢ Highlights on: Business line Advanced Technologies for T
Slide 116: Start-ups expected to break-even in Year 3
Start-ups expected to break-even on Year 3 and typically reach Group’s profitability objectives in the following years Illustration Start-ups development: 1) Large investments have short-term dilutive impact on Group’s margins and FCF Example of a typical Eurofins’ start-up: 2) Growth momentum allow
Slide 117: Growth, Profitability and ROCE are critical objectives
Growth, Profitability and ROCE are critical objectives Group Profitability Objectives ▪ Operating margin developing towards mid- term profitability objective 1. Start of profit contribution from start-ups 2. Investments in large industrialized laboratories unlock operational leverage ▪ A target “cru
Eurofins Scientific — Investor Presentation (September 2020) on 6ix